INH

INH154 is a highly potent inhibitor of Nek2 and Hec1 binding (INH), with IC50 values of 120 nM in MB468 cells and 200 nM in Hela cells.

Isoniazid (Isonicotinic hydrazide) is an antibacterial agent used primarily as a tuberculostatic.

INH1 (IBT13131) is a cell-permeable Hec1 inhibitor that specifically disrupts the Hec1/Nek2 interaction.

UTA1inh-C1 is a novel inhibitor of kidney urea transporter UT-A1.

RNF5 inhibitor inh-02 is a selective inhibitor of the ubiquitin ligase RNF5/RMA1, which can significantly rescue F508del-CFTR (cystic fibrosis transmembrane conductance regulator with a deletion at position 508 of phenylalanine) and regulate ATG4B and paxillin, making it useful for studying cystic fibrosis (CF).

INH14 is a novel inhibitor of the IKKα/β-dependent TLR inflammatory response (IC50s: 8.97/3.59 μM for IKKα/IKKβ).

INH6, an effective Hec1 inhibitor, selectively disrupts the Hec1/Nek2 interaction and induces chromosome mis-alignment.

INH-13 is a Aurora inhibitor.

CFTR(inh)-172 (CFTR Inhibitor-172) is a voltage-independent, selective CFTR inhibitor.

T16A(inh)-B01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class B inhibitor.

T16A(inh)-C01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class C inhibitor.

T16A(inh)-D01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class D inhibitor.

UTA1inh-A1 is a novel inhibitor of kidney urea transporter UT-A1.

UTA1inh-B1 is a novel inhibitor of kidney urea transporter UT-A1.

UTA1inh-D1 is a novel inhibitor of kidney urea transporter UT-A1 .

ODN INH-1, a palindromic and class R ('restricted') inhibitory ODN, is a potent inhibitor of TLR9-induced B cells and macrophages.

Inh2-B1 is an inhibitor targeting STK1 (Ser/Thr protein kinase) by directly binding to its ATP-binding catalytic domain. STK1 is a crucial component in the cell wall biosynthesis of Staphylococcus aureus and a key factor in MRSA resistance. Consequently, Inh2-B1 is regarded as an "antibiotic resistance breaker" with the ability to prevent biofilm formation.

PAT1inh-B01 hydrochloride is a selective SLC26A6 inhibitor. It inhibits the anion exchange mediated by PAT1 (Cl-/HCO3- exchanger) with an IC50 of 350 nM. This compound blocks fluid absorption in the small intestine and can be used for research into diseases related to insufficient intestinal secretion.

PAT1inh-B01, a selective SLC26A6 inhibitor, impedes PAT1 (a Cl-/HCO3- exchanger) activity, with an IC50 of 350 nM, effectively inhibiting anion exchange. It also obstructs fluid absorption in the small intestine and is utilized in the study of small intestinal hyposecretory disorders [1].

PAT1inh-A0030 is a selective inhibitor of PAT1 (SLC26A6) with an IC 50 value of 1.0 μM. It inhibits fluid absorption in the ileum of wild-type and cystic fibrosis (CF) mice (CftrdelF508/delF508) in a closed-loop model of intestinal fluid absorption and can be used in the study of intestinal diseases related to CF [1].

T3Inh-1 is a potent and selective ppGalNAc-T3 inhibitor with IC50 of 7 µM. T3Inh-1 protects against breast cancer cells. T3Inh-1 reduces FGF23 hormone levels in tissue cells and mice without causing any toxic side effects.

Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM, demonstrating approximately 3,700-fold greater selectivity for Aurora B over Aurora A.

MK-8712 is a monobactam beta-lactamase inhibitor.

Tefibazumab is a humanised monoclonal antibody targeting ClfA (clumping factor A), indicated for the treatment of Staphylococcus aureus bacteraemia.